Last reviewed · How we verify
Intraperitoneal Lignocaine
Intraperioneal Lignocaine, marketed by the Jawaharlal Institute of Postgraduate Medical Education & Research, holds a niche position in the pharmaceutical market with its unique intraperitoneal administration. The drug's key strength lies in its key composition patent, which is set to expire in 2028, providing a period of exclusivity and potential market protection. The primary risk is the lack of clear revenue data and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | Intraperitoneal Lignocaine |
|---|---|
| Also known as | IP Lignocaine |
| Sponsor | Jawaharlal Institute of Postgraduate Medical Education & Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Analgesic Effect of IntraPeritoneal LIGNOcaine in Gynaecological Open Surgery (NA)
- Compared With Different Method for Postcesarean Section Analgesia (NA)
- The Impact of Intraperitoneal Spray Combined With Intravenous Lidocaine on Postoperative Pain After Myomectomy (NA)
- Effect of Three Different Postcesarean Analgesic Techniques on QbsQor-10 Score (NA)
- Intraperitoneal Local Anesthetic Infiltration Versus Erector Spinae Block in Laparoscopic Cholecystectomy
- The Ideal Local Anesthetic for Intraperitoneal Gallbladder Bed Infiltration Following Laparoscopic Cholecystectomy (NA)
- Postoperative Analgesia in Laparoscopic Gynecological Surgeries (PHASE4)
- Comparing QLB Type I Block to Intraperitoneal Instillation Added to Wound Infiltration for Postoperative Cesarian Pain (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |